Is the robotic approach the future of distal pancreatectomy with splenectomy? A propensity score matched analysis
AbstractOur study provides a comparative analysis of the Laparo-Endoscopic Single Site (LESS) and robotic surgical approaches for distal pancreatectomy and splenectomy, examining their cosmetic advantages, patient outcomes, and operative efficiencies through propensity score matching (PSM). We prospectively followed 174 patients undergoing either the LESS or robotic procedure, matched by cell type, tumor size, age, sex, and BMI from 2012 to 2023. Propensity score matching (PSM) was utilized for data adjustment, with results presented as median (mean ± SD). Post-PSM analysis showed no significant differences in age or...
Source: Journal of Robotic Surgery - April 2, 2024 Category: Surgery Source Type: research
Thrombosis Tendency After Splenectomy in a Danish Family With Hemoglobin Volga, and a Literature Review
. (Source: Hemoglobin)
Source: Hemoglobin - April 2, 2024 Category: Hematology Authors: Johanne Kodal BreinholtAndreas Glenth øjMustafa Vakur Bora Department of Clinical Biochemistry, University Hospital of Southern Denmark, Esbjerg, Denmarkb Danish Red Blood Cell Center, Copenhagen University Hospital, Rigshospitalet, Denmarkc Department o Source Type: research
Retracted: Effects of Omega-3 Polyunsaturated Fatty Acids on Cognitive Function after Splenectomy in Rats
Biomed Res Int. 2024 Mar 20;2024:9802612. doi: 10.1155/2024/9802612. eCollection 2024.ABSTRACT[This retracts the article DOI: 10.1155/2021/5513886.].PMID:38550186 | PMC:PMC10973251 | DOI:10.1155/2024/9802612 (Source: Biomed Res)
Source: Biomed Res - March 29, 2024 Category: Research Authors: BioMed Research International Source Type: research
Retracted: Effects of Omega-3 Polyunsaturated Fatty Acids on Cognitive Function after Splenectomy in Rats
Biomed Res Int. 2024 Mar 20;2024:9802612. doi: 10.1155/2024/9802612. eCollection 2024.ABSTRACT[This retracts the article DOI: 10.1155/2021/5513886.].PMID:38550186 | PMC:PMC10973251 | DOI:10.1155/2024/9802612 (Source: Biomed Res)
Source: Biomed Res - March 29, 2024 Category: Research Authors: BioMed Research International Source Type: research
Thrombopoietin Receptor Agonists and Other Second-Line Therapies for Immune Thrombocytopenia: A Narrative Review With a Focus on Drug Access in Canada
DISCUSSION: TPO-RAs are effective second-line therapies for the treatment of ITP; however, access is variable across Canada, which results in health disparities and poor uptake of international treatment guidelines.PMID:38546381 | DOI:10.3138/cim-2024-2569 (Source: Clinical and Investigative Medicine)
Source: Clinical and Investigative Medicine - March 28, 2024 Category: Biomedical Science Authors: Joanne Britto Anne Holbrook Haowei Sun Christine Cserti-Gazdewich Oksana Prokopchuk-Gauk Cyrus Hsia Karima Khamisa Paul R Yenson Michelle Sholzberg Harold J Olney Sudeep Shivakumar David Jones Hayley Merkeley Jacqueline Costello Erin Jamula Donald M Arnol Source Type: research
Thrombopoietin Receptor Agonists and Other Second-Line Therapies for Immune Thrombocytopenia: A Narrative Review With a Focus on Drug Access in Canada
DISCUSSION: TPO-RAs are effective second-line therapies for the treatment of ITP; however, access is variable across Canada, which results in health disparities and poor uptake of international treatment guidelines.PMID:38546381 | DOI:10.3138/cim-2024-2569 (Source: Clinical and Investigative Medicine)
Source: Clinical and Investigative Medicine - March 28, 2024 Category: Biomedical Science Authors: Joanne Britto Anne Holbrook Haowei Sun Christine Cserti-Gazdewich Oksana Prokopchuk-Gauk Cyrus Hsia Karima Khamisa Paul R Yenson Michelle Sholzberg Harold J Olney Sudeep Shivakumar David Jones Hayley Merkeley Jacqueline Costello Erin Jamula Donald M Arnol Source Type: research
Thrombopoietin Receptor Agonists and Other Second-Line Therapies for Immune Thrombocytopenia: A Narrative Review With a Focus on Drug Access in Canada
DISCUSSION: TPO-RAs are effective second-line therapies for the treatment of ITP; however, access is variable across Canada, which results in health disparities and poor uptake of international treatment guidelines.PMID:38546381 | DOI:10.3138/cim-2024-2569 (Source: Clinical and Investigative Medicine)
Source: Clinical and Investigative Medicine - March 28, 2024 Category: Biomedical Science Authors: Joanne Britto Anne Holbrook Haowei Sun Christine Cserti-Gazdewich Oksana Prokopchuk-Gauk Cyrus Hsia Karima Khamisa Paul R Yenson Michelle Sholzberg Harold J Olney Sudeep Shivakumar David Jones Hayley Merkeley Jacqueline Costello Erin Jamula Donald M Arnol Source Type: research
Thrombopoietin Receptor Agonists and Other Second-Line Therapies for Immune Thrombocytopenia: A Narrative Review With a Focus on Drug Access in Canada
DISCUSSION: TPO-RAs are effective second-line therapies for the treatment of ITP; however, access is variable across Canada, which results in health disparities and poor uptake of international treatment guidelines.PMID:38546381 | DOI:10.3138/cim-2024-2569 (Source: Clinical and Investigative Medicine)
Source: Clinical and Investigative Medicine - March 28, 2024 Category: Biomedical Science Authors: Joanne Britto Anne Holbrook Haowei Sun Christine Cserti-Gazdewich Oksana Prokopchuk-Gauk Cyrus Hsia Karima Khamisa Paul R Yenson Michelle Sholzberg Harold J Olney Sudeep Shivakumar David Jones Hayley Merkeley Jacqueline Costello Erin Jamula Donald M Arnol Source Type: research
Thrombopoietin Receptor Agonists and Other Second-Line Therapies for Immune Thrombocytopenia: A Narrative Review With a Focus on Drug Access in Canada
DISCUSSION: TPO-RAs are effective second-line therapies for the treatment of ITP; however, access is variable across Canada, which results in health disparities and poor uptake of international treatment guidelines.PMID:38546381 | DOI:10.3138/cim-2024-2569 (Source: Clinical and Investigative Medicine)
Source: Clinical and Investigative Medicine - March 28, 2024 Category: Biomedical Science Authors: Joanne Britto Anne Holbrook Haowei Sun Christine Cserti-Gazdewich Oksana Prokopchuk-Gauk Cyrus Hsia Karima Khamisa Paul R Yenson Michelle Sholzberg Harold J Olney Sudeep Shivakumar David Jones Hayley Merkeley Jacqueline Costello Erin Jamula Donald M Arnol Source Type: research
Thrombopoietin Receptor Agonists and Other Second-Line Therapies for Immune Thrombocytopenia: A Narrative Review With a Focus on Drug Access in Canada
DISCUSSION: TPO-RAs are effective second-line therapies for the treatment of ITP; however, access is variable across Canada, which results in health disparities and poor uptake of international treatment guidelines.PMID:38546381 | DOI:10.3138/cim-2024-2569 (Source: Clinical and Investigative Medicine)
Source: Clinical and Investigative Medicine - March 28, 2024 Category: Biomedical Science Authors: Joanne Britto Anne Holbrook Haowei Sun Christine Cserti-Gazdewich Oksana Prokopchuk-Gauk Cyrus Hsia Karima Khamisa Paul R Yenson Michelle Sholzberg Harold J Olney Sudeep Shivakumar David Jones Hayley Merkeley Jacqueline Costello Erin Jamula Donald M Arnol Source Type: research
Thrombopoietin Receptor Agonists and Other Second-Line Therapies for Immune Thrombocytopenia: A Narrative Review With a Focus on Drug Access in Canada
DISCUSSION: TPO-RAs are effective second-line therapies for the treatment of ITP; however, access is variable across Canada, which results in health disparities and poor uptake of international treatment guidelines.PMID:38546381 | DOI:10.3138/cim-2024-2569 (Source: Clinical and Investigative Medicine)
Source: Clinical and Investigative Medicine - March 28, 2024 Category: Biomedical Science Authors: Joanne Britto Anne Holbrook Haowei Sun Christine Cserti-Gazdewich Oksana Prokopchuk-Gauk Cyrus Hsia Karima Khamisa Paul R Yenson Michelle Sholzberg Harold J Olney Sudeep Shivakumar David Jones Hayley Merkeley Jacqueline Costello Erin Jamula Donald M Arnol Source Type: research
Thrombopoietin Receptor Agonists and Other Second-Line Therapies for Immune Thrombocytopenia: A Narrative Review With a Focus on Drug Access in Canada
DISCUSSION: TPO-RAs are effective second-line therapies for the treatment of ITP; however, access is variable across Canada, which results in health disparities and poor uptake of international treatment guidelines.PMID:38546381 | DOI:10.3138/cim-2024-2569 (Source: Clinical and Investigative Medicine)
Source: Clinical and Investigative Medicine - March 28, 2024 Category: Biomedical Science Authors: Joanne Britto Anne Holbrook Haowei Sun Christine Cserti-Gazdewich Oksana Prokopchuk-Gauk Cyrus Hsia Karima Khamisa Paul R Yenson Michelle Sholzberg Harold J Olney Sudeep Shivakumar David Jones Hayley Merkeley Jacqueline Costello Erin Jamula Donald M Arnol Source Type: research
